Equities Analysts Issue Forecasts for DMAC Q1 Earnings

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) – Research analysts at HC Wainwright lifted their Q1 2026 EPS estimates for shares of DiaMedica Therapeutics in a report released on Wednesday, April 1st. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($0.17) per share for the quarter, up from their previous forecast of ($0.18). The consensus estimate for DiaMedica Therapeutics’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.75) EPS and FY2028 earnings at ($0.35) EPS.

DMAC has been the topic of several other research reports. Lake Street Capital reaffirmed a “buy” rating on shares of DiaMedica Therapeutics in a report on Monday, January 5th. Weiss Ratings restated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Wednesday, January 21st. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $12.33.

DiaMedica Therapeutics Stock Performance

Shares of NASDAQ:DMAC opened at $6.48 on Friday. The stock has a market capitalization of $349.14 million, a price-to-earnings ratio of -9.26 and a beta of 1.16. DiaMedica Therapeutics has a 1-year low of $3.19 and a 1-year high of $10.42. The company has a 50 day moving average price of $7.80 and a 200 day moving average price of $7.64.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its earnings results on Monday, March 30th. The company reported ($0.17) EPS for the quarter, hitting analysts’ consensus estimates of ($0.17). The business had revenue of ($0.03) million during the quarter, compared to the consensus estimate of $13.50 million.

Hedge Funds Weigh In On DiaMedica Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cooperman Leon G lifted its stake in DiaMedica Therapeutics by 98.2% in the third quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock valued at $22,463,000 after acquiring an additional 1,619,761 shares during the last quarter. Millennium Management LLC acquired a new position in shares of DiaMedica Therapeutics during the 3rd quarter worth $8,157,000. Geode Capital Management LLC raised its holdings in shares of DiaMedica Therapeutics by 99.6% during the 2nd quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock valued at $2,458,000 after purchasing an additional 314,407 shares in the last quarter. Paragon Associates & Paragon Associates II Joint Venture raised its holdings in shares of DiaMedica Therapeutics by 34.6% during the 3rd quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company’s stock valued at $6,011,000 after purchasing an additional 225,000 shares in the last quarter. Finally, Royal Bank of Canada lifted its stake in shares of DiaMedica Therapeutics by 46,879.1% in the 1st quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after purchasing an additional 154,701 shares during the last quarter. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics News Summary

Here are the key news stories impacting DiaMedica Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed expected quarterly losses across 2026 — raising Q1 to ($0.17), Q2 to ($0.18), Q3 to ($0.19) and Q4 to ($0.21) EPS (less negative than prior forecasts). These revisions narrow projected losses for FY2026 and FY2027 (both raised to ($0.75)). The smaller-than-expected losses improve the earnings trajectory and are a near‑term positive for the stock.
• Positive Sentiment: HC Wainwright also raised its FY2028 estimate to ($0.35) from ($0.37) and issued a long‑term profitable outlook for FY2030 at $0.56 EPS — signaling a path to sustained profitability over the next few years, which supports a higher valuation multiple for this biotech developer.
• Neutral Sentiment: Recent Q4 2025 earnings call transcript is available for investors who want detail on management commentary, clinical progress and cash runway; the call itself didn’t contain a separate headline announcement beyond the reported results. Earnings Call Transcript
• Negative Sentiment: HC Wainwright slightly lowered its FY2029 EPS view to $0.14 from $0.15 — a small downward revision that may temper enthusiasm among investors focused on nearer‑term upside to consensus large positive numbers in later years.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.